IGM Biosciences, Inc.
10
0
0
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 100/100
80.0%
8 terminated/withdrawn out of 10 trials
11.1%
-75.4% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
Role: lead
A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid Arthritis
Role: lead
A Study of Imvotamab in Active, Refractory Idiopathic Inflammatory Myopathies
Role: lead
A Study of Imvotamab in Severe Systemic Lupus Erythematosus
Role: lead
Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma
Role: lead
Evaluation of IGM-7354 in Adults With Relapsed and/or Refractory Cancer
Role: lead
A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma
Role: lead
Expanded Access of Imvotamab (IGM-2323) in Patients With R/R NHL
Role: lead
Evaluation of IGM-6268 in Healthy Volunteers
Role: lead
Evaluation of IGM-6268 in Healthy Adults and Patients With Mild to Moderate COVID-19
Role: lead
All 10 trials loaded